^
Association details:
Biomarker:EIF4EBP1 expression
Cancer:Thymic Carcinoma
Drug:everolimus (mTOR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy

Excerpt:
This was a single-arm, single-stage, open-label, multicenter, phase II trial. Patients received oral everolimus 10 mg/d until disease progression, unacceptable toxicity, or patient refusal....A statistically significantly shorter survival was observed in patients with a tumor positivity for p4E-BP1 (P < .001) and for IGF1R (P = .023)....The expression of p4E-BP1 was statistically significantly higher in patients with TC than in those with T (57% v 10%; P = .003).
DOI:
10.1200/JCO.2017.74.4078
Trial ID: